Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > REGULATORY
REGULATORY
- Selexipag Designated as Orphan Drug for CTEPH: MHLW
June 21, 2016
- PMDA to Boost Transparency in Expert Consultation Process by Confirming Donations from Competitors
June 21, 2016
- PMDA Beats FY2015 Review Time Targets
June 20, 2016
- MHLW Unveils List of Switch OTCs Eligible for Tax Break
June 20, 2016
- Anti-HIV Drug Genvoya Approved in Japan
June 20, 2016
- MHLW Reprimands Bipha Over Leakage of Recombinant Organisms in Manufacturing Process for Medway Injection
June 20, 2016
- Kaketsuken-Like Cases Seen Outside Japan Too, Many Exposed through Tip-Offs: PMDA
June 17, 2016
- MHLW Study Group Approves Interim Report toward Full-Scale Operation of MID-NET Database
June 17, 2016
- First Generics for 8 APIs to Join NHI Price List on June 17, 40% Price Rule Applied to Olanzapine
June 16, 2016
- Greater than Expected Need for Drug Discovery Research Using Existing Drugs: AMED Project
June 16, 2016
- MHLW Personnel Reshuffle Announced; Nakayama to Lead FY2018 Drug Pricing Reform
June 15, 2016
- Harvoni, Sovaldi under Review for Risks of Hypertension, Cerebrovascular Disorder
June 13, 2016
- MHLW to Set Up Subcommittee to Help Implement AMR Action Plan
June 13, 2016
- AMED to Establish New Scheme to Support Commercialization of Drug Seeds from Academia
June 10, 2016
- MHLW to Revise Guidelines on Use of Blood Products
June 10, 2016
- Upcoming ICH Meeting Expected to Approve New Members Including Generic Drug Organization
June 9, 2016
- Company Funding for AMED-Backed Clinical Research Also Subject to Legal Regulation: Govt
June 8, 2016
- Use of MID-NET in PMS Could Promote Comparisons of One’s Own Products with Other Treatments: FPMAJ Official
June 7, 2016
- MHLW to Place 2-Year Grace Period on Mandatory Barcode Labeling by March 2021 for Companies with “Special Circumstances”
June 6, 2016
- 141 Trials of Nucleic Acid Drugs Underway Worldwide, but 70% Being Conducted by US Companies: JPO Survey
June 6, 2016
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…